Voriconazole: A novel treatment option for cryptococcal meningitis

Infectious Diseases

Volumn 47, Issue 10, 2015, Pages 694-700

  Yao, Yan ^a   Zhang, Jia Tang ^a   Yan, Bo ^a   Gao, Ting ^a   Xing, Xiao Wei ^a   Tian, Cheng Lin ^a   Huang, Xu Sheng ^a   Yu, Sheng Yuan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Antifungal drug; Cryptococcal meningitis; CSF India ink staining; Fluconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE; INDIAN INK; VORICONAZOLE; ANTIFUNGAL AGENT; CARBON; INK;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CRYPTOCOCCAL MENINGITIS; DIAGNOSTIC ERROR; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STAINING; TERTIARY CARE CENTER; TREATMENT FAILURE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHINA; COMBINATION DRUG THERAPY; CRYPTOCOCCUS NEOFORMANS; ISOLATION AND PURIFICATION; MENINGITIS, CRYPTOCOCCAL; MICROBIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; TIME FACTOR;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CARBON; CHINA; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC ERRORS; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; VORICONAZOLE;

EID: 84962564054     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1044260     Document Type: Article

References (20)

1. Mitchell TG, Perfect Jr. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans Clin Microbiol Rev 1995; 8: 515-48.
2. Pappas P G, Perfect J R, Cloud G A, Larsen R A, Pankey G A, Lancaster DJ, et al Cryotococcosis in human immunodefi-ciency virus-negative patients in the era of effective azole therapy HIV/AIDS CID 2001; 33: 691-9.
3. Vidal JE, Penalva de Oliveira A C, Dauar RF Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America Braz J Infect Dis 2013; 17: 353-62.
4. S hih CC, Chen Y C, Chang SC, Luh KT, Hsieh WC Cryptococcal meningitis in non-HIV-infected patients QJ Med 2000; 93: 245-51.
5. Perfect J R, Dismukes W E, Dromer F, Goldman D L, Graybill JR, Harrison TS, et al Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America Clin Infect Dis 2010; 50: 291-322.
6. World Health Organization Rapid advice: diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children WHO Document Production Services; 2011 pp 1-37.
7. Lentnek A, Sande MA, Whetley RJ, McCracken GH, Scheld WM Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis Clin Infect Dis 1992; 15(Suppl 1): S189-94.
8. Day JN, Chau T T, Wolbers M, Mai PP, Dung NT, Mai NH, et al Combination antifungal therapy for cryptococcal meningitis NEngl J Med 2013; 368: 1291-302.
9. Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanc T, Bishop L, et al Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-Associated cryptococcal meningitis Clin Infect Dis 2012; 54: 121-8.
10. Bandettini R, Castagnola E, Calvillo M, Micalizzi C, Raveqnani M, Pescetto L, et al Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant JChemother 2009; 21: 108-9.
11. Nierenberg NE, Thompson GR, Lewis JS, Hogan BK, Patterson TF Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir Med Mycol 2010; 48: 532-6.
12. Sabbatani S, Manfredi R, Pavoni M, Consales A, Chiodo F.Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIVnegative patient, after fluconazole failure Mycopathologia 2004; 158: 165-71.
13. Elenkov I.Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being Neurochem Int 2008; 52: 40-51.
14. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, et al The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000 HIV/AIDS CID 2003; 36: 789-94.
15. Lee Y-C, Wang J-T, Sun H-Y, Chen Y-C Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection JMicrobiol Immunol 2011; 44: 338-45.
16. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G.Symptomatic relapse of HIV-Associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution Clin Infect Dis 2006; 43: 1069-73.
17. Brew B J.Cryptococcal meningitis In: HIV neurology Oxford University Press; 2001 pp 91-6.
18. Kirkpatrick WR, Najvar LK, Bocanegra R, Patterson TF, Graybill Jr. New guinea pig model of cryptococcal meningitis Antimicrob Agents Chemother 2007; 51: 3011-13.
19. Mavrogiorgos N, Zaragoza O, Casadevall A, Nosanchuk J D.Efficacy of voriconazole in experimental Cryptococcus neoformans infection Mycopathologia 2006; 162: 111-14.
20. Zhong Y-H, Tan F, Li M, Liu J, Wang X, Yuan Y, e t al Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection Int J Infect Dis 2014; 20: 31-6.